This invention is a method of killing the stealthy intra-cellular bacteria which cause many Th1 and `Autoimmune` diseases. The methods described in this invention will treat and prevent the diseases customarily named Diabetes Type 1, Diabetes Type 2, Rheumatic Arthritis, Reactive Arthritis, Osteo Arthritis, Psoriasis, Scleroderma, Osteoporosis, Atherosclerosis, Myocarditis, Endocarditis, Pericarditis, Alzheimer's, Cystic Fibrosis, Hashimoto's Thyroiditis, Graves Disease, Leprosy, Syphilis, Lyme, Chronic Lyme, Borreliosis, Neuro-borreliosis, Inflammatory Bowel Disease (IBD), Tuberculosis, Latent Tuberculosis, Sarcoidosis, Neurosarcoidosis, Lupus, Discoid Lupus, Lupus Pernio, Lupus Nephritis, Systemic Lupus Erythematosis (SLE), Asthma, Macular Degeneration, Uveitis, Crohn's, Irritable Bowel Syndrome, Sjogren's, Fibromyalgia, Chronic Fatigue Syndrom (CFS), Chronic Fatigue Immune Dysfunction Syndrome (CFIDS), Myalgic Encephalitis (ME), Amyotrophic Lateral Sclerosis (ALS), Parkinson's, Multiple Sclerosis, Autism Spectrum Disorder (ASD), Attention Deficit Disorder (ADD), and Attention Deficit Hyperactivity Disorder (ADHD). This invention achieves this by reducing the ability of the stealthy bacteria to produce proteins with their 70S Ribosome. The 30S and 50S subunits of the bacterial ribosome are targeted individually and collectively. Further, this invention reduces the availability of Angiotensin II to the host's Angiotensin receptors, conditioning the immune system to recognize and kill the bacteria. Finally, this invention reduces the availability of Angiotensin II and cytokines to the bacterial pathogens and thus inhibits the ability of their genome to scavenge (from a host patient) the amino acids, and other biochemicals necessary for bacterial survival.

tuberculosis/fatica

Treatment and prevention of Th1 and `autoimmune` diseases effected with antibiotics and/or angiotensin inhibition

Il database di erbe medicinali più completo supportato dalla scienza